GlassScriptPhysician profile
Melissa K Manriques
NPI 1679564140
$3,587.13
in general payments reported to CMS, 2019-2025
16 companies · $939 in 2025
The $939 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $596 · 2023: $959 · 2024: $702 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.49 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $920.56 | 2021-2025 | Opzelura, Opzelura, Iclusig |
| Abbvie INC. | $536.90 | 2021-2025 | |
| Pfizer INC. | $469.06 | 2021-2024 | |
| Leo Pharma INC. | $287.69 | 2023-2025 | Adbry |
| Galderma Laboratories, L.P. | $274.73 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $250.00 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $149.58 | 2022-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.83 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $138.71 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $138.21 | 2021-2024 | Tremfya |
| Genzyme Corporation | $90.96 | 2023-2025 | |
| Biofrontera INC. | $59.90 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $47.45 | 2023-2024 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $34.04 | 2022 | |
| Allergan, INC. | $29.51 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $19.00 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Manriques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.